InvestMoat
Robotic Surgery | Medical Devices | AIGold Standard

Intuitive Surgical, Inc.

ISRG~$150B capAnalysed Oct 10

Hold

Hold for Long-Term Compounding

71
MoatMoat narrowing over 5–10 years71
Growth78
Val64
0255075100

Combined average of Moat (AI Resilience), Growth, and Valuation scores.

71/100

The most durable razor-and-blades moat in medical devices — once a hospital installs da Vinci and trains its surgeons, switching is a career-level commitment measured in years, not months.

Intuitive Surgical's moat is built on Installed Base Lock-In and Surgeon Muscle Memory:

  • The Surgeon Training Moat: A surgeon who spends 2-5 years mastering the da Vinci console develops deeply ingrained psychomotor skills that do not transfer to a competing platform. Retraining on Medtronic's Hugo or J&J's Ottava is not a software migration — it is a manual dexterity re-education. Hospitals that switch face surgeon credentialing delays, OR scheduling disruption, and patient outcome uncertainty.
  • Razor-and-Blades at Scale: Intuitive sells capital equipment (da Vinci systems) at relatively modest margins, then earns 80%+ gross margins on the single-use instruments and accessories that are consumed in every procedure. With 11,710 da Vinci systems in the installed base (June 30, 2026) generating an average of 400+ procedures per year, this creates a durable, inflation-resistant recurring revenue stream that grows automatically with procedure volume.
  • Outcomes Data Head Start: Over 14 million da Vinci procedures have generated the world's largest proprietary robotic surgery outcomes database. This data advantage enables faster FDA clearance for new indications, stronger clinical evidence for hospital purchasing committees, and continuous software improvement — a real head start, though rivals' platforms generate the same kind of case data as their installed bases grow, so it is scale rather than exclusivity.
  • da Vinci 5 Platform Refresh: Launched in 2024, da Vinci 5 introduces force feedback, 10,000x more computing power, and AI-assisted surgical guidance. The upgrade cycle refreshes switching cost lock-in for the existing installed base while expanding Intuitive's AI surgery leadership. Each new system sold today embeds Intuitive deeper into hospital infrastructure for the next 10-15 years.

AI is a net tailwind for Intuitive Surgical. Unlike software companies where AI threatens to commoditize the product, AI strengthens Intuitive's moat by adding guided surgery intelligence on top of the installed base — creating a new monetization layer without displacing the physical lock-in. The primary competitive risk is not AI but well-funded platform challengers (Medtronic, J&J) in the next 5-10 years.

71.4 resilient · 72.6 vulnerable · 80/20 = 71.6 · = 72 · blended with 67 projected = 71

Open a moat to read its note.

AI-Vulnerable Moats1 strong · 3 intact · 1 N/A
AI-Resilient Moats1 strong · 4 intact · 2 N/A

The regulatory lead is the one pillar likely to step down. The lock rested on rivals needing years of clearances per indication, and that gap is closing: Hugo is cleared in US urology and filed for general surgery and gynecology, and J&J's Ottava won a De Novo in July 2026 for general surgery. The surgeon console habit, per-procedure instrument revenue and the 14M-procedure outcomes data hold, because they sit on the 11,710-system installed base that a new clearance does not move. A rival taking procedures inside hospitals that already own da Vinci would be a separate status question on learned interfaces, not part of this trend.

72 today → 67 if the trend completes · scored 71 (70/30)

Is Intuitive Surgical stock a buy?

We rate Intuitive Surgical Hold, with a composite score of 71/100: moat 71, growth 78 and valuation 64. The valuation score is struck against our bear, base and bull targets and moves with the price.

What is Intuitive Surgical's moat?

Intuitive Surgical scores 71/100 on moat. The most durable razor-and-blades moat in medical devices — once a hospital installs da Vinci and trains its surgeons, switching is a career-level commitment measured in years, not months.

How fast is Intuitive Surgical expected to grow?

We estimate 13-17% a year over the next three to five years, for a growth score of 78/100.

What is Intuitive Surgical's price target?

Our base case is $415, with $270 in the bear case and $560 in the bull case.